{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:13:07Z","timestamp":1791825187811,"version":"4.3.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Bayerisches Zentrum f\u00fcr Pr\u00e4ventive Infektionsmedizin","award":["not yet available"],"award-info":[{"award-number":["not yet available"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    The primary purpose of this study was to assess the prevalence and the antimicrobial susceptibility rates of carbapenemase-producing Enterobacterales (CPE) in a German University Hospital during a 5-year period. From January 2020 to December 2024, all Enterobacterales detected were molecularly investigated for carbapenemases in every case of elevated minimum inhibitory concentration of ertapenem, meropenem, or imipenem. Subsequently, CPE were tested for susceptibility to reserve antibiotics. Overall, 101 CPE were identified. Most of the CPE strains harbored only one carbapenemase gene, such as\n                    <jats:italic toggle=\"yes\">\n                      bla\n                      <jats:sub>OXA-48<\/jats:sub>\n                    <\/jats:italic>\n                    (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 32, 31.6%),\n                    <jats:italic toggle=\"yes\">\n                      bla\n                      <jats:sub>NDM<\/jats:sub>\n                    <\/jats:italic>\n                    (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 27, 26.7%), and\n                    <jats:italic toggle=\"yes\">\n                      bla\n                      <jats:sub>VIM<\/jats:sub>\n                    <\/jats:italic>\n                    (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 14, 13.8%). The annual number of CPE detected increased during the observation period (2020,\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 5; 2021,\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 5; 2022,\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 24; 2023,\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 29; 2024,\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 38). We also observed a progressive rise of the proportion of CPE harboring a metallo-\u03b2-lactamase gene such as\n                    <jats:italic toggle=\"yes\">\n                      bla\n                      <jats:sub>NDM<\/jats:sub>\n                    <\/jats:italic>\n                    or\n                    <jats:italic toggle=\"yes\">\n                      bla\n                      <jats:sub>VIM<\/jats:sub>\n                    <\/jats:italic>\n                    (2020, 0.0%; 2021, 0.0%; 2022, 50.0%; 2023, 55.2%; 2024, 65.8%). Regarding the antimicrobial susceptibility, only 3.3% of all CPE isolates tested showed resistance to aztreonam\/avibactam. In contrast, the resistance rates for cefiderocol and ceftazidime\/avibactam amounted respectively to 12.8% and 53.9%. The increasing annual number of CPE at our hospital is associated with a rise of the proportion of metallo-\u03b2-lactamase-producing strains. The newly available antibiotic aztreonam\/avibactam showed promising\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity against CPE.\n                  <\/jats:p>","DOI":"10.1177\/10766294251384459","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:45:21Z","timestamp":1759247121000},"page":"374-379","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Epidemiology and Antimicrobial Susceptibility of Carbapenemase-Producing Enterobacterales from a German University Hospital During a 5-Year Period"],"prefix":"10.1177","volume":"31","author":[{"given":"Julius","family":"Sommer","sequence":"first","affiliation":[{"name":"Mikrobiologisches Institut \u2013 Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Esse","sequence":"additional","affiliation":[{"name":"Mikrobiologisches Institut \u2013 Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Held","sequence":"additional","affiliation":[{"name":"Mikrobiologisches Institut \u2013 Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Voigtl\u00e4nder","sequence":"additional","affiliation":[{"name":"Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, N\u00fcrnberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bogdan","sequence":"additional","affiliation":[{"name":"Mikrobiologisches Institut \u2013 Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany."},{"name":"FAU Profile Center Immunomedicine, Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Valenza","sequence":"additional","affiliation":[{"name":"Mikrobiologisches Institut \u2013 Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-818619-0.00029-0"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"e_1_3_5_4_2","volume-title":"Antimicrobial Resistance Surveillance in Europe 2023 \u2013 2021 data","author":"European Centre for Disease Prevention and Control","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2023 \u2013 2021 data. European Centre for Disease Prevention and Control."},{"key":"e_1_3_5_5_2","unstructured":"European Centre for Disease Prevention and Control. Rapid risk assessment - Carbapenem-resistant Enterobacterales \u2013 third update. 2025."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.09.002"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00001-07"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-022-01843-6"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05035-11"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2023.11.016"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.004"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(20000215)19:3<335:aid-sim336>3.0.co;2-z"},{"key":"e_1_3_5_13_2","volume-title":"Statistics in Epidemiology: Methods, Techniques, and Applications","author":"Sahai H","year":"1996","unstructured":"Sahai H, , Khurshid A. (1996) Statistics in Epidemiology: Methods, Techniques, and Applications. Boca Raton, FL: CRC Press, Inc."},{"key":"e_1_3_5_14_2","first-page":"3","article-title":"Report of the national reference center for gram-negative hospital pathogens\u2014Period January 1, 2023 to December 31, 2023","volume":"2","author":"Pfennigwerth N","year":"2025","unstructured":"Pfennigwerth N, , Cremanns M, , Eisfeld J, et al. Report of the national reference center for gram-negative hospital pathogens\u2014Period January 1, 2023 to December 31, 2023. Epid Bull, 2025; 2:3\u201311.","journal-title":"Epid Bull"},{"issue":"19","key":"e_1_3_5_15_2","first-page":"1143","article-title":"Gram-negative pathogens (3MRGN\/4MRGN): frequency and features","volume":"149","author":"Pfennigwerth N","year":"2024","unstructured":"Pfennigwerth N, , Gatermann S. Gram-negative pathogens (3MRGN\/4MRGN): frequency and features. Dtsch Med Wochenschr, 2024; 149(19):1143\u20131150.","journal-title":"Dtsch Med Wochenschr"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2022.10.007"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01142-24"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02136-2"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.5.230202e"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02061-4"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.04.394"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.09.005"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10081012"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01659-20"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04181-23"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1673731"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10766294251384459","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10766294251384459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10766294251384459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:20:35Z","timestamp":1777684835000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/10766294251384459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/10766294251384459"],"URL":"https:\/\/doi.org\/10.1177\/10766294251384459","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}